Found 5 results

Name Type of Offering Accepted Date
AsclepiX Therapeutics, LLC See All Filings
D 2017-02-09 16:18:21
Amount To Be Raised $1,000,000
Associated Brokers / Dealers N/A
CIK Number 0001697751
Filed Document 0001697751-17-000001
Exclusions or Exemptions 506b
Accepted Date 2017-02-09 16:18:21
Type of Offering D
Industry Biotechnology
Offering Tier N/A
Principal Place of Business MARYLAND
Revenue or Assets Decline to Disclose
Type of Security Debt
AsclepiX Therapeutics, Inc. See All Filings
D 2018-10-25 16:36:07
Amount To Be Raised $7,500,000
Associated Brokers / Dealers N/A
CIK Number 0001697751
Filed Document 0001697751-18-000004
Exclusions or Exemptions 506b
Accepted Date 2018-10-25 16:36:07
Type of Offering D
Industry Biotechnology
Offering Tier N/A
Principal Place of Business MARYLAND
Revenue or Assets Decline to Disclose
Type of Security Debt
AsclepiX Therapeutics, Inc. See All Filings
D 2020-06-11 11:36:40
Amount To Be Raised $35,000,000
Associated Brokers / Dealers N/A
CIK Number 0001697751
Filed Document 0001697751-20-000001
Exclusions or Exemptions 506b
Accepted Date 2020-06-11 11:36:40
Type of Offering D
Industry Biotechnology
Offering Tier N/A
Principal Place of Business MARYLAND
Revenue or Assets Decline to Disclose
Type of Security Equity
AsclepiX Therapeutics, Inc. See All Filings
D/A 2019-06-17 16:41:02
Amount To Be Raised $10,000,000
Associated Brokers / Dealers N/A
CIK Number 0001697751
Filed Document 0001697751-19-000001
Exclusions or Exemptions 506b
Accepted Date 2019-06-17 16:41:02
Type of Offering D/A
Industry Biotechnology
Offering Tier N/A
Principal Place of Business MARYLAND
Revenue or Assets Decline to Disclose
Type of Security Debt
AsclepiX Therapeutics, Inc. See All Filings
D 2024-04-26 13:07:32
Amount To Be Raised $12,544,498
Associated Brokers / Dealers N/A
CIK Number 0001697751
Filed Document 0001697751-24-000003
Exclusions or Exemptions 506b
Accepted Date 2024-04-26 13:07:32
Type of Offering D
Industry Biotechnology
Offering Tier N/A
Principal Place of Business MARYLAND
Revenue or Assets Decline to Disclose
Type of Security Equity